{"id":"W2762643147","doi":"10.1093/annonc/mdx364.015","title":"KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Placebo; Oncology; Breast cancer; Chemotherapy; Internal medicine; Adjuvant; Cancer; Alternative medicine; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001606722,0.002298217,0.002800482,0.0005475299,0.0004640688,0.001505658,0.001498405,0.001978997,0.01188882],"category_scores_gemma":[0.001015916,0.0009073413,0.001985139,0.0004649302,0.001206939,0.00131034,0.0004321245,0.004743108,0.002507751],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009860209,"about_ca_system_score_gemma":0.001594132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001597671,"about_ca_topic_score_gemma":0.003586502,"domain_scores_codex":[0.9996283,0.0001586063,0.00001508148,0.00008043383,0.00002598466,0.00009151756],"domain_scores_gemma":[0.999416,0.0001038018,0.00009906307,0.00005597741,0.00003317258,0.0002921458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.948887,0.01853889,0.0003474242,0.0005931485,0.0006844872,0.00003834156,0.00004987975,0.0006170792,0.01032881,0.0002172307,0.001948924,0.01774875],"study_design_scores_gemma":[0.8905978,0.1055896,0.001024248,0.00002402219,0.0003692998,0.00003124676,0.00002317825,0.0002692169,0.0009817918,0.000138266,0.0009365111,0.00001489819],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9727345,0.005146503,0.00114242,0.001873254,0.001284289,0.005668049,0.005456946,0.0003789096,0.006315292],"genre_scores_gemma":[0.9588118,0.005133833,0.003351703,0.002779828,0.0009429663,0.007776981,0.005528438,0.0001244199,0.01555008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01188882,"threshold_uncertainty_score":0.03977209,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05267274810334072,"score_gpt":0.4156776529951707,"score_spread":0.36300490489183,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}